{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:53Z","timestamp":1790740613197,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of integrase strand-transfer inhibitors (INSTIs) on steatotic liver disease in women with HIV (WWH) is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using data collected in the Women's Interagency HIV Study from 2007\u20132020, change in Fibrosis-4 index (FIB4), aspartate aminotransferase to platelet ratio index (APRI), and nonalcoholic fatty liver disease fibrosis score (NFS) over 5 years was compared between virologically suppressed WWH who switched to or added an INSTI to their antiretroviral therapy (ART) and WWH remaining on non-INSTI ART. In participants with transient elastography (TE) measures, estimates of hepatic steatosis (controlled attenuation parameter [CAP]), fibrosis (liver stiffness [LS]), and steatohepatitis (FibroScan-aspartate aminotransferase [FAST] scores) were compared by group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 872 WWH (323 INSTI, 549 non-INSTI) were included, and 280 (146 INSTI, 134 non-INSTI) had TE. Of these, 61% were non-Hispanic Black; mean age was 47 years and body mass index was 31.4\u2005kg\/m2. Among non-obese women, those in the INSTI versus non-INSTI group had a greater increase in NFS (but not FIB4 or APRI) over time (study group \u00d7 time, P = .015). Those in the INSTI versus non-INSTI group also had greater CAP (+25; 95% CI: .28\u201349; P = .048), LS (+1.23; 1.01\u20131.49; P = .038), and FAST scores (+1.97; 1.17\u20133.31; P = .011) and a 3.7 (1.2\u201311.4; P = .021) greater odds of having hepatic steatosis (CAP \u2265248\u2005dB\/m) within 1 year of starting an INSTI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Hepatic steatosis risk was increased only within the first year following INSTI initiation among WWH. Longitudinal hepatic assessments are warranted to evaluate whether these changes are associated with clinically significant liver disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaf049","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:46:51Z","timestamp":1738583211000},"page":"304-313","source":"Crossref","is-referenced-by-count":12,"title":["Noninvasive Markers of Hepatic Steatosis and Fibrosis Following Integrase Strand-Transfer Inhibitor Initiation in Women With HIV"],"prefix":"10.1093","volume":"81","author":[{"given":"Michael Andrew","family":"Yu","sequence":"first","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Gerig","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-7983","authenticated-orcid":false,"given":"C Christina","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joffi","family":"Musonge-Effoe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-1903","authenticated-orcid":false,"given":"Igho","family":"Ofotokun","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6305-2727","authenticated-orcid":false,"given":"Anandi N","family":"Sheth","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed K","family":"Ali","sequence":"additional","affiliation":[{"name":"Emory Global Diabetes Research Center, Woodruff Health Sciences Center and Emory University , Atlanta, Georgia ,","place":["USA"]},{"name":"Department of Family and Preventive Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8102-288X","authenticated-orcid":false,"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9011-8456","authenticated-orcid":false,"given":"Amanda B","family":"Spence","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Georgetown University Medical Center , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-0145","authenticated-orcid":false,"given":"Maria L","family":"Alcaide","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Miller School of Medicine, University of Miami , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B","family":"Dumond","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-0565","authenticated-orcid":false,"given":"Alison G","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Colorado School of Public Health , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey L","family":"French","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Stroger Hospital of Cook County Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Augenbraun","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, SUNY Downstate Health Sciences University , Brooklyn, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Anastos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albert Einstein College of Medicine , Bronx, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C","family":"Price","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-6770","authenticated-orcid":false,"given":"Phyllis C","family":"Tien","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and San Francisco VA Health Care System, University of California San Francisco School of Medicine , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-8266","authenticated-orcid":false,"given":"Cecile D","family":"Lahiri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine Atlanta, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2025091916591295200_ciaf049-B1","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection","volume":"31","author":"Maurice","year":"2017","journal-title":"AIDS"},{"key":"2025091916591295200_ciaf049-B2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/HEP.0000000000000313","article-title":"Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study","volume":"78","author":"Gawrieh","year":"2023","journal-title":"Hepatology"},{"key":"2025091916591295200_ciaf049-B3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cgh.2023.01.001","article-title":"Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta-analysis","volume":"21","author":"Kalligeros","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025091916591295200_ciaf049-B4","doi-asserted-by":"crossref","first-page":"e140134","DOI":"10.1172\/jci.insight.140134","article-title":"Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD","volume":"5","author":"Fourman","year":"2020","journal-title":"JCI Insight"},{"key":"2025091916591295200_ciaf049-B5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cgh.2020.10.018","article-title":"Expert panel review on non-alcoholic fatty liver disease in persons with HIV","volume":"20","author":"Lake","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025091916591295200_ciaf049-B6","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025091916591295200_ciaf049-B7","doi-asserted-by":"crossref","first-page":"ofy201","DOI":"10.1093\/ofid\/ofy201","article-title":"Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race","volume":"5","author":"Bhagwat","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025091916591295200_ciaf049-B8","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2025091916591295200_ciaf049-B9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"NAMSAL ANRS 12313 Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091916591295200_ciaf049-B10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciz853","article-title":"Weight gain associated with integrase stand transfer inhibitor use in women","volume":"71","author":"Kerchberger","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciae474","article-title":"Short and long-term body weight change following the switch to or the addition of integrase inhibitors in persons with HIV differs by sex","volume":"80","author":"Lahiri","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B12","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"2025091916591295200_ciaf049-B14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025091916591295200_ciaf049-B15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091916591295200_ciaf049-B17","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1093\/cid\/ciab057","article-title":"Hepatic steatosis associated with exposure to elvitegravir and raltegravir","volume":"73","author":"Kirkegaard-Klitbo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B18","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/cix467","article-title":"Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus\u2013infected patients with nonalcoholic fatty liver disease","volume":"65","author":"Mac\u00edas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/23744235.2019.1629008","article-title":"Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease","volume":"51","author":"Calza","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2025091916591295200_ciaf049-B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/ije\/dyy021","article-title":"Cohort profile: the Women's Interagency HIV Study (WIHS)","volume":"47","author":"Adimora","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2025091916591295200_ciaf049-B21","doi-asserted-by":"crossref","first-page":"e055706","DOI":"10.1136\/bmjopen-2021-055706","article-title":"Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV","volume":"12","author":"Price","year":"2022","journal-title":"BMJ Open"},{"key":"2025091916591295200_ciaf049-B22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1517\/17425255.2010.513383","article-title":"Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies","volume":"6","author":"Burger","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025091916591295200_ciaf049-B23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025091916591295200_ciaf049-B24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"2025091916591295200_ciaf049-B25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11904-020-00531-0","article-title":"NASH in HIV","volume":"17","author":"Cervo","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025091916591295200_ciaf049-B26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"2025091916591295200_ciaf049-B27","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1097\/QAD.0000000000003351","article-title":"Controlled attenuation parameter accurately detects liver steatosis in people with HIV","volume":"36","author":"Duarte","year":"2022","journal-title":"AIDS"},{"key":"2025091916591295200_ciaf049-B28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2017.03.016","article-title":"American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases","volume":"152","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"key":"2025091916591295200_ciaf049-B29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091916591295200_ciaf049-B30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025091916591295200_ciaf049-B31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12879-023-08530-3","article-title":"The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naive to antiretroviral therapy","volume":"23","author":"Fernandes","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2025091916591295200_ciaf049-B32","author":"Lahiri"},{"key":"2025091916591295200_ciaf049-B33","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","article-title":"Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity","volume":"45","author":"Drolz","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2025091916591295200_ciaf049-B34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/cix467","article-title":"Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease","volume":"65","author":"Mac\u00edas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/ciad203","article-title":"Fibroscan-aspartate aminotransferase (FAST) score predicts liver-related outcomes, but not extra-hepatic events, in a multicenter cohort of people with HIV","volume":"77","author":"Sebastiani","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025091916591295200_ciaf049-B36","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3748\/wjg.v26.i39.5919","article-title":"Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease","volume":"26","author":"Campos-Murgu\u00eda","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2025091916591295200_ciaf049-B37","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/QAI.0000000000001936","article-title":"Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study","volume":"80","author":"Lemoine","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025091916591295200_ciaf049-B38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/humupd\/dmac045","article-title":"Anti-Mullerian hormone for the diagnosis and prediction of menopause: a systematic review","volume":"29","author":"Nelson","year":"2023","journal-title":"Hum Reprod Update"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf049\/61741826\/ciaf049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/304\/61741826\/ciaf049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/2\/304\/61741826\/ciaf049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:59:23Z","timestamp":1758315563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/2\/304\/7997404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf049","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,15]]},"published":{"date-parts":[[2025,2,3]]}}}